You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 12, 2025

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Netherlands: These 2 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Netherlands: These 2 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026" DrugPatentWatch.com thinkBiotech, 2025 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can LYRICA CR (pregabalin) generic drug versions launch?

Generic name: pregabalin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2025
Generic Entry Controlled by: Netherlands Patent 2,000,281
Patent Title: Vaste farmaceutische samenstellingen die pregabaline bevatten.

Drug Price Trends for LYRICA CR
LYRICA CR is a drug marketed by Upjohn. There are three patents protecting this drug and four Paragraph IV challenges. Six tentatively approved generics are ready to enter the market.

This drug has thirty-seven patent family members in thirty-three countries.

See drug price trends for LYRICA CR.

The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-three suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.

When can KOSELUGO (selumetinib sulfate) generic drug versions launch?

Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2025
Generic Entry Controlled by: Netherlands Patent 301,139

KOSELUGO is a drug marketed by Astrazeneca. There are six patents protecting this drug.

This drug has one hundred and ninety-eight patent family members in forty-four countries.

See drug price trends for KOSELUGO.

The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.

Market Analysis and Financial Projection

The Netherlands' pharmaceutical market is navigating a dynamic landscape marked by growth in branded drugs, regulatory evolution, and challenges in generic drug accessibility. Valued at XX million in 2025 with a projected 5.80% CAGR through 2033[1], the market is driven by an aging population, chronic disease prevalence, and technological innovation[1][5]. Here's an in-depth analysis:


Market Overview

Branded Drugs Dominate: Patented medicines accounted for 61% of the 2022 market ($4.31bn), while generics held 27% ($1.91bn)[6]. Major players like Pfizer, Novartis, and Johnson & Johnson lead this concentrated market (top 10 firms >60% share)[1].

Growth Drivers:

  • Innovation Focus: Specialty drugs, biosimilars, and personalized medicine[1][5].
  • Regulatory Hub: The EMA’s Amsterdam presence boosts R&D investment, with pharmaceuticals contributing 8% to industrial value[5].
  • Patent Expiries: Key drugs like semaglutide (Ozempic) and pregabalin (Lyrica CR) face patent cliffs in 2025, opening opportunities for generics[3].

Forecast: Pharmaceutical sales are projected to rise from $6.49B PPP in 2024 to $6.72B PPP by 2028[7].


Generic Drug Challenges

Pricing Pressures:

  • Low Price Ceilings: Generics enter at 25% of originator prices, falling to 40% within two years—far below the 80% seen in the U.S.[6].
  • Shortages: Drug shortages surged 51% in 2023 (2,292 cases), with 68% linked to generics[2]. ABN AMRO argues raising price ceilings by 25% (costing €170M, 0.3% of healthcare spending) could mitigate this[2][6].

Regulatory Hurdles:

  • Preference Policies: Insurers often select a single supplier via tenders, increasing shortage risks[2].
  • Over-Regulation: Complex approval processes delay generics, despite bioequivalence standards[6][14].

Market Fragmentation: Generics face competition from OTC drugs and magistral compounding (e.g., CDCA for CTX patients, priced 25x lower than branded alternatives)[8].


Regulatory Opportunities

EU Policy Shifts:

  • HTA Regulation (2025): Joint EU clinical assessments for oncology/ATMPs could streamline approvals[11].
  • Pharma Package Reforms: Proposed EU legislation (targeting 2028–2029) aims to balance innovation and affordability[11].

National Initiatives:

  • Small-Scale Experiments: The NZa’s 2025 framework encourages trialing innovations (e.g., telemedicine) under coverage-with-evidence programs[15].
  • Generic Substitution: Dutch prescribers increasingly use INN names, with generics now >50% of prescriptions[10][13].

Strategic Considerations

For Branded Drug Makers:

  • Focus on biosimilars and orphan drugs (e.g., CDCA Leadiant case[8]).
  • Leverage EMA proximity for faster centralized approvals[4][12].

For Generics:

  • Advocate for pricing reforms ([2] suggests matching Belgium/Germany’s 25% higher ceilings).
  • Capitalize on 2025 patent expiries[3], though global API shortages remain a risk[6].

Policy Recommendations:

  • Multi-Supplier Tenders: Avoid reliance on single suppliers to enhance resilience[2].
  • EU-Wide Coordination: Address cross-border pricing disparities and API dependencies[2][6].

Future Outlook

While branded drugs drive innovation, generics’ growth hinges on resolving pricing and regulatory bottlenecks. The 2025–2030 period will test the Netherlands’ ability to balance cost containment with sustainable access, particularly as EU reforms reshape market dynamics.

"The large shortage of generic medicines is mainly caused by the fact that neighbouring countries pay 25% more for medicines."
— Anja van Balen, ABN AMRO Healthcare Sector Banker[2].

References

  1. https://www.datainsightsmarket.com/reports/pharmaceutical-market-in-netherlands-7489
  2. https://www.euractiv.com/section/health-consumers/news/netherlands-should-raise-generics-prices-to-combat-drug-shortages-says-dutch-bank/
  3. https://www.drugpatentwatch.com/p/generic-entry-opportunity-date/Netherlands
  4. https://english.cbg-meb.nl/sections/marketing-authorisation-medicines-for-human-use
  5. https://think.ing.com/articles/dutch-manufacturing-comeback-2025/
  6. https://pharmexcil.com/uploads/countryreports/Netherlands.pdf
  7. https://www.reportlinker.com/dataset/cdd34a7caca3e84d5b179f88fd5db1bfc6cc15b3
  8. https://www.pharmaceuticalaccountability.org/wp-content/uploads/2025/02/20250213-Verdict-Rotterdam-District-Court-in-Leadiant-vs-ACM_ECLI_NL_RBROT_2025_1811-ENGLISH-inofficial-translation.pdf
  9. https://www.gabionline.net/country-focus/the-netherlands/Policies-and-Legislation
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3107776/
  11. https://www.aoshearman.com/insights/ao-shearman-on-life-sciences/key-regulatory-changes-impacting-the-healthcare-industry-in-the-eu-and-germany-in-2025
  12. https://pubmed.ncbi.nlm.nih.gov/38679943/
  13. https://gabionline.net/es/enfoque-por-pais/the-netherlands
  14. https://www.gabionline.net/country-focus/the-netherlands/Licensing-Guidelines-and-Regulations
  15. https://mtrconsult.com/news/dutch-healthcare-authority-updates-policy-framework-small-scale-experiments-2025
Last updated: 2025-03-20

More… ↓

⤷  Try for Free

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.